News & Events about Sarepta Therapeutics Inc.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced it had completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). Sarepta received a payment of $102 million upon completion of the sale. Sarepta was awarded...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at Cowen's 2nd Annual RNA Therapeutics Summit on Monday, July 10, 2023 at 11:00 a.m. E.T. The fireside chat will be held...
TipRanks Financial Blog
1 year ago
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT Research Report), Int... Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT Research Report), Intercept...
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus based gene therapy for the treatment of...